SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Federspiel A)
 

Sökning: WFRF:(Federspiel A) > A Consensus-Develop...

  • Elvebakken, HegeNorwegian Univ Sci & Technol, Fac Med & Hlth Sci, Dept Clin & Mol Med, Trondheim, Norway.;More & Romsdal Hosp Trust, Alesund Hosp, Dept Oncol, Alesund, Norway. (författare)

A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2020-10-01
  • S. Karger,2021
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-470057
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-470057URI
  • https://doi.org/10.1159/000511905DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are classified according to morphology as well-differentiated neuroendocrine tumours (NETs) G3 or poorly differentiated neuroendocrine carcinomas (NECs). Little data exist concerning which morphological criteria this subdivision should be based on. Uncertainty exists if the NEC group should be further subdivided according to proliferation rate. Clinical data on NET G3 and NEC with a lower Ki-67 range are limited. A total of 213 patients with high-grade GEP-NEN (Ki-67 >20%) were included from the Nordic NEC Registries. Four experienced NET pathologists re-evaluated the cases to develop the best morphological criteria to separate NET G3 from NEC, assuming longer survival in NET G3. Organoid growth pattern, capillary network in direct contact to tumour cells, and absence of desmoplastic stroma were found to best separate NET G3 from NEC. Of 196 patients with metastatic disease, NET G3 was found in 12.3%, NEC with a Ki-67 <55% (NEC < 55) in 29.6%, and NEC with a Ki-67 >= 55% (NEC >= 55) in 56.6%. Only in 1.5%, the morphology was ambiguous. Of 164 patients receiving first-line chemotherapy, 88% received platinum/etoposide treatment. Response rate was higher for NEC >= 55 (44%) than that of NEC < 55 (25%) and NET G3 (24%) (p = 0.025 and p = 0.026). Median progression-free survival was 5 months for all groups. Median overall survival was 33 months for NET G3 compared to 11 months for both NEC < 55 and NEC >= 55 (p = 0.004 and 0.003). Specific morphological criteria can separate NET G3 from NECs and show prognostic significance. High-grade GEP-NEN patients stratified by morphology and proliferation rate demonstrate significant differences in response to chemotherapy and survival.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Perren, AurelUniv Bern, Inst Pathol, Bern, Switzerland. (författare)
  • Scoazec, Jean-YvesInst Gustave Roussy, Dept Biopathol, Villejuif, France. (författare)
  • Tang, Laura H.Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA. (författare)
  • Federspiel, BirgitteCopenhagen Univ Hosp, Dept Pathol, Rigshosp, Copenhagen, Denmark. (författare)
  • Klimstra, David S.Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA. (författare)
  • Vestermark, Lene W.Odense Univ Hosp, Dept Oncol, Odense, Denmark. (författare)
  • Ali, Abir,1986-Uppsala universitet,Onkologisk endokrinologi(Swepub:uu)abali010 (författare)
  • Zlobec, Inti (författare)
  • Myklebust, Tor A.More & Romsdal Hosp Trust, Dept Res & Innovat, Alesund, Norway.;Canc Registry Norway, Dept Registrat, Oslo, Norway. (författare)
  • Hjortland, Geir O.Oslo Univ Hosp, Dept Oncol, Oslo, Norway. (författare)
  • Langer, Seppo W.Copenhagen Univ Hosp, Dept Oncol, Rigshosp, Copenhagen, Denmark. (författare)
  • Gronbaek, HenningAarhus Univ Hosp, Dept Hepatol & Gastroenterol, Aarhus, Denmark.;ENETS Ctr Excellence, Aarhus, Denmark. (författare)
  • Knigge, UlrichUniv Copenhagen, Fac Hlth Sci, Dept Surg & Endocrinol PE C, Rigshosp, Copenhagen, Denmark. (författare)
  • Tiensuu Janson, EvaUppsala universitet,Onkologisk endokrinologi(Swepub:uu)evatieja (författare)
  • Sorbye, HalfdanHaukeland Hosp, Dept Oncol, Bergen, Norway.;Univ Bergen, Dept Clin Sci, Bergen, Norway. (författare)
  • Norwegian Univ Sci & Technol, Fac Med & Hlth Sci, Dept Clin & Mol Med, Trondheim, Norway.;More & Romsdal Hosp Trust, Alesund Hosp, Dept Oncol, Alesund, Norway.Univ Bern, Inst Pathol, Bern, Switzerland. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Neuroendocrinology: S. Karger111:9, s. 883-8940028-38351423-0194

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy